The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine

Adv Drug Deliv Rev. 2021 Jul:174:337-347. doi: 10.1016/j.addr.2021.04.028. Epub 2021 May 4.

Abstract

Males and females have physiological, hormonal, and genetic differences that can cause different responses to medicinal treatments. The role of sex in the pharmacokinetics and pharmacodynamics of drugs is well established in the literature. However, researchers have yet to robustly and consistently consider the impact of sex differences on the pharmacokinetics and pharmacodynamics of nanomedicine formulations when designing nanomedicine therapeutics and/or constructing clinical trials. In this review, we highlight the physiological and anatomical differences between sexes and discuss how these differences can influence the therapeutic efficacy, side effects, and drug delivery safety of nanomedicine products. A deep understanding of the effects of sex on nano-based drug delivery agents will robustly improve the risk assessment process, resulting in safer formulations, successful clinical translation, and improved therapeutic efficacies for both sexes.

Keywords: Nanomedicine; Sex-specific response; Therapeutic efficacy.

Publication types

  • Review

MeSH terms

  • Animals
  • Chemistry, Pharmaceutical / methods
  • Drug Delivery Systems*
  • Drug Design*
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Female
  • Humans
  • Male
  • Nanomedicine
  • Nanoparticles*
  • Pharmacokinetics
  • Sex Factors